Furthermore, we found no significant difference in OS outcomes for patients with tumours that had mutations in the MAPK pathway module genes of the ERK1/2 pathway (median survival = 58.6 months) versus those of the ERK5 pathway (60.7 months; p = 0.4); the ERK1/2 pathways genes versus those of the p38 pathway (59.1 months; p = 0.078); and the ERK5 pathway genes versus those of the p38 pathway (p = 0.74; Fig. 2f; also see Supplementary File 2 for all pairwise comparisons). This evidence concerns the gene CRK and neoplasm.